Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Scientists have linked roughly five percent of adult cancers to mutations in genes called FOCAD and TTC37. Another gene known ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

It’s important to control where CRISPR goes, and when the CRISPR action takes place, so it doesn’t cause problems elsewhere in the body.” Gonzalez-Fernandez recently secured funding through ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Germany came out with a double action gene modification method, called CRISRP-Cas9. This is a mechanism that can edit the genomes of humans, pathogens, and plants. CRISPR stands for Clustered ...

It's important to control where CRISPR goes, and when the CRISPR action takes place, so it doesn't cause problems elsewhere in the body." Tomas Gonzalez-Fernandez, assistant professor of ...

A team from UNIGE, the Max Planck Institute for Molecular Physiology in Dortmund, and Heinrich Heine University in Düsseldorf ...